Cardlytics Inc (CDLX)

Company filed Charter Amendment on June 3, 2026, effecting a 1-for-10 reverse stock split and reducing authorized shares.

Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

The published measure or accounting basis is not supported by an exact source binding.

Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Nasdaq delisting notice issued June 2026; stock price dropped 47.8% over 21 days to $1.80.

Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

FY2026-Q2; GAAP. Published target: >=37.5 USD_MILLIONS. Same fiscal period as the stored target.

Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.